Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Aim of the present study is to investigate whether baseline or early post-treatment (one
month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs
OR CD4+/CD25high/FOXP3+ T cells), known to suppress antitumor immune response, may influence
long-term clinical outcome (i.e. radiological response, progression-free survival or overall
survival) in metastatic colorectal cancer patients treated with a standard first-line
chemotherapy including fluorouracil, irinotecan and bevacizumab